BMS
FDA warns BMS over manufacturing plant in Puerto Rico
September 15, 2010Manufacturing and Production BMS, FDA, GMP, Puerto Rico
A plant operated by Bristol-Myers Squibb in Puerto Rico has been cited by the US Food and Drug Administration for …
NICE won’t approve Abilify without more data
September 13, 2010Sales and Marketing Abilify, BMS, NICE
NICE is unlikely to approve Bristol-Myers Squibb’s schizophrenia drug Abilify unless the company can provide more data on its clinical …
BMS appoints UK market access director
September 13, 2010Sales and Marketing BMS, UK, appointment, sales and marketing
Patrick Hopkinson has joined Bristol-Myers Squibb as director of market access and external affairs in the UK. He joins the …
BMS to acquire ZymoGenetics
September 8, 2010Research and Development, Sales and Marketing BMS, hepatitis
Bristol-Myers Squibb is to acquire biopharma company ZymoGenetics for $885 million to add to its ‘string of pearls’of small biotech …
BMS’ melanoma drug given priority review
August 19, 2010Sales and Marketing BMS, ipilimumab
Bristol-Myers Squibb’s promising new treatment for skin cancer melanoma has been given a priority review by the FDA. The company …
Excipient problem leads to Coumadin recall
July 20, 2010Manufacturing and Production BMS, manufacturing compliance, recalls
Bristol-Myers Squibb is recalling nearly 150,000 tablets of its anticoagulant product Coumadin distributed across the US because some of them …
Pharma manufacturing news in brief
July 6, 2010Manufacturing and Production BMS, Borregaard Synthesis, Colorcon, JHP Pharma, Saltigo, Sanofi-Aventis, Synthetech, Viropharma, univar
New capital investments from Sanofi-Aventis, Bristol-Myers Squibb, Viropharma and Colorcon head up this round-up of developments in the pharmaceutical manufacturing …
BMS factory closure could interrupt HIV drug supply
June 11, 2010Manufacturing and Production BMS, HIV, manufacturing, supply chain
Closure of a manufacturing facility in France operated by Bristol-Myers Squibb could lead to shortages of an important treatment for …
BMS on tenterhooks over belatacept future
May 4, 2010Research and Development BMS, belatacept
Bristol-Myers Squibb has been kept on tenterhooks by US regulator the FDA over the future of its investigational kidney transplant …
Plavix boosts BMS first quarter figures
April 30, 2010Sales and Marketing BMS, Plavix
Plavix has boosted Bristol-Myers Squibb’s performance in the first quarter of the year, with sales of the anti-clotting blockbuster up …
Phase III success for apixaban
March 5, 2010Research and Development BMS, Pfizer, VTE, apixaban
Pfizer and Bristol-Myers Squibb’s apixaban has shown promising results in a late-stage head-to-head trial with Sanofi-Aventis’ Lovenox. The oral anti-coagulant …
Lamberto Andreotti new head of Bristol-Myers Squibb
March 4, 2010Research and Development, Sales and Marketing BMS, appointment, research and development, sales and marketing
Bristol-Myers Squibb has appointed Lamberto Andreotti its new chief executive with effect from 4 May, succeeding James Cornelius who will …
NICE warns industry on cost-effectiveness
February 9, 2010Sales and Marketing BMS, Janssen, NICE, Novartis, hta
NICE has turned down three drugs on cost grounds and has urged the pharma industry to do more to help …
BMS profits buoyant after Mead Johnson jettisoned
February 1, 2010Sales and Marketing 2009 financials, BMS, Mead Johnson
Bristol-Myers Squibb’s have revealed continued strong sales of the anti-blood clotting treatment Plavix and the antipsychotic Abilify and a huge …
Orencia wins expanded European licence
January 27, 2010Sales and Marketing BMS, Orencia, rheumatoid arthritis
BMS’s Orencia has been approved in Europe to treat children aged six and over who suffer from a form of …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
